Free Trial
NYSEAMERICAN:NBY

NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

NovaBay Pharmaceuticals logo
$0.59 0.00 (-0.58%)
As of 05/2/2025 04:10 PM Eastern

About NovaBay Pharmaceuticals Stock (NYSEAMERICAN:NBY)

Key Stats

Today's Range
$0.56
$0.59
50-Day Range
$0.47
$0.65
52-Week Range
$0.36
$9.08
Volume
26,202 shs
Average Volume
922,757 shs
Market Capitalization
$2.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NovaBay Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
9th Percentile Overall Score

NBY MarketRank™: 

NovaBay Pharmaceuticals scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for NovaBay Pharmaceuticals.

  • Earnings Growth

    Earnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($2.54) to ($0.55) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NovaBay Pharmaceuticals is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NovaBay Pharmaceuticals is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NovaBay Pharmaceuticals has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about NovaBay Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    3.31% of the float of NovaBay Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    NovaBay Pharmaceuticals has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NovaBay Pharmaceuticals has recently increased by 321.41%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    NovaBay Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    NovaBay Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.31% of the float of NovaBay Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    NovaBay Pharmaceuticals has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NovaBay Pharmaceuticals has recently increased by 321.41%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    NovaBay Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • Insider Buying vs. Insider Selling

    In the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.30% of the stock of NovaBay Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 1.34% of the stock of NovaBay Pharmaceuticals is held by institutions.

  • Read more about NovaBay Pharmaceuticals' insider trading history.
Receive NBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NBY Stock News Headlines

The Man I Turn to In Times Like This
A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
NovaBay Pharmaceuticals, Inc. (B9P0.F)
See More Headlines

NBY Stock Analysis - Frequently Asked Questions

NovaBay Pharmaceuticals' stock was trading at $0.58 at the beginning of the year. Since then, NBY stock has increased by 1.1% and is now trading at $0.5866.
View the best growth stocks for 2025 here
.

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) issued its earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts' consensus estimates of ($1.40) by $0.35. The biopharmaceutical company had revenue of $1.84 million for the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 146.20% and a negative net margin of 79.70%.

NovaBay Pharmaceuticals shares reverse split on the morning of Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), Tesla (TSLA) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
11/11/2021
Today
5/03/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:NBY
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,610,000.00
Pretax Margin
-79.70%

Debt

Sales & Book Value

Annual Sales
$14.40 million
Price / Cash Flow
N/A
Book Value
$1.53 per share
Price / Book
0.38

Miscellaneous

Free Float
4,160,000
Market Cap
$2.47 million
Optionable
Not Optionable
Beta
2.82
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NYSEAMERICAN:NBY) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners